))
Goal – Deliver Cancer Drugs Faster: Dr. Marie-Agnès Doucey, Calico Biosystems
Manage episode 430315881 series 3469528
Innhold levert av Alex Jani: interviewing visionaries of healthcare innovation. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Alex Jani: interviewing visionaries of healthcare innovation eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Do you know what is the % of cancer drug candidates that fail in human trials?
Guess, and I bet you underestimated it.
This is what we speak at the beginning of this episode and what my guest wants to change dramatically.
You will also hear about:
- the % of patients that actually benefit from approved cancer drug therapies (spoiler: so so low)
- cancer monotherapies vs. cancer combination therapies
- how to reproduce the human cancer ecosystem from a tumor
- precision oncology
- multiomics analysis
- and how to bring cancer drugs faster to patients
Dr. Marie-Agnès Doucey, the co-founder of Calico Biosystems, is a biotechnology engineer with a PhD in biochemistry. She has over 15 years of experience in R&D and drug development programs in oncology.
Calico Biosystems is a Swiss startup developing a drug testing platform that uses patients’ tumors, multiomics profiling, and computational modeling to predict the clinical efficacy of anti-cancer drugs at the pre-clinical stage. Radically accelerating drug development.
Here is their website:
https://calicobiosystems.com/
0:00 Dr. Marie-Agnès Doucey and Calico Biosystems
1:15 Why Only 10% of Cancer Patients Benefit from Therapies
9:00 Complexity of Experimental Oncology
12:50 Cancer Monotherapies vs. Cancer Combination Therapies
15:11 How to Reproduce Human Cancer Ecosystem
17:10 What is Precision Oncology
20:35 Platform for Cancer Drug Developers Instead of Animal Models
32:34 Collaboration with the University of Lausanne
37:49 What is Multiomics Analysis
40:35 De-risking Clinical Studies and Moving to the Clinical Stage
47:16 More Than a Decade of Research to Found a Startup
53:07 Thank You, Follow Calico Biosystems
53:55 Follow X-Health.show, Disclaimer
If you've enjoyed listening, you'll make us happy by clicking "Follow" on X-Health.show and leaving a review.
The information in this podcast is for informational purposes only and should not be considered medical advice. If you have any medical questions, please consult your healthcare practitioner. The opinions on the show are Alex's or her guests. The podcast does not make any responsibility or warranties about guests statements or credibility. While the podcast makes every effort to ensure that the information shared is accurate, please let us know if you have any comments, suggestions or corrections.
Kapitler
1. Dr. Marie-Agnès Doucey and Calico Biosystems (00:00:00)
2. Why Only 10% of Cancer Patients Benefit from Therapies (00:01:15)
3. Complexity of Experimental Oncology (00:09:00)
4. Cancer Monotherapies vs. Cancer Combination Therapies (00:12:50)
5. How to Reproduce Human Cancer Ecosystem (00:15:11)
6. What is Precision Oncology (00:17:10)
7. Platform for Cancer Drug Developers Instead of Animal Models (00:20:35)
8. Collaboration with the University of Lausanne (00:32:34)
9. What is Multiomics Analysis (00:37:49)
10. De-risking Clinical Studies and Moving to the Clinical Stage (00:40:35)
11. More Than a Decade of Research to Found a Startup (00:47:16)
12. Thank You, Follow Calico Biosystems (00:53:07)
13. Follow X-Health.show, Disclaimer (00:53:55)
82 episoder
Del
